Product Information

Description

TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with. Locally Advanced or Metastatic Breast Cancer: 1 Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. (1.1, 14.1), 2 Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. (1.1, 14.2).

Sacituzumab govitecan-hziy is a Trop-2 directed antibody and topoisomerase inhibitor conjugate, composed of the following three components: 1 the humanized monoclonal antibody, hRS7 IgG1? (also called sacituzumab), which binds to Trop-2 (the trophoblast cell-surface antigen-2);, 2 the drug SN-38, a topoisomerase inhibitor;, 3 a hydrolysable linker (called CL2A), which links the humanized monoclonal antibody to SN-38.